Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Revenue (2017 - 2025)

UroGen Pharma's Revenue history spans 9 years, with the latest figure at $37.8 million for Q4 2025.

  • For Q4 2025, Revenue rose 54.03% year-over-year to $37.8 million; the TTM value through Dec 2025 reached $109.8 million, up 21.45%, while the annual FY2025 figure was $109.8 million, 21.45% up from the prior year.
  • Revenue reached $37.8 million in Q4 2025 per URGN's latest filing, up from $27.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $37.8 million in Q4 2025 to a low of $7.5 million in Q1 2021.
  • Average Revenue over 5 years is $19.8 million, with a median of $19.5 million recorded in 2024.
  • Peak YoY movement for Revenue: skyrocketed 3403.23% in 2021, then grew 3.35% in 2024.
  • A 5-year view of Revenue shows it stood at $16.2 million in 2021, then increased by 11.86% to $18.1 million in 2022, then soared by 30.06% to $23.5 million in 2023, then rose by 4.4% to $24.6 million in 2024, then surged by 54.03% to $37.8 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Revenue are $37.8 million (Q4 2025), $27.5 million (Q3 2025), and $24.2 million (Q2 2025).